nach oben

Erschienen in:

01.10.2010 | Review

Cardiological evaluation after cerebral ischaemia

Consensus statement of the Working Group Heart and Brain of the German Cardiac Society—Cardiovascular Research (DGK) and the German Stroke Society (DSG)

verfasst von: Ulrich Laufs, Uta C. Hoppe, Stephan Rosenkranz, Paulus Kirchhof, Michael Böhm, Hans-Christoph Diener, Matthias Endres, Martin Grond, Werner Hacke, Thomas Meinertz, E. Bernd Ringelstein, Joachim Röther, Martin Dichgans

Erschienen in: Clinical Research in Cardiology | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

The cardiological evaluation of patients with cerebral ischaemia is of great clinical importance because diseases of the heart and aorta represent important sources of embolism, because ischaemic stroke is an index event that can lead to the diagnosis of cardiovascular diseases and because the mortality and morbidity of stroke patients are determined by concomitant cardiac diseases. Despite the importance of cardiological examinations for patients with ischaemic strokes, the topic is only addressed by few prospective clinical studies. Therefore, this interdisciplinary consensus document was developed to summarise the available information and to make expert recommendations for the evaluation of cardiovascular risk markers, electrocardiographic examinations, echocardiography and the indications for further investigations of a cardiac disease.

Ringleb PA et al (2009) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee. http://www.eso-stroke.org/pdf/ESO%20Guidelines_update_Jan_2009.pdf

Capes SE, Hunt D, Malmberg K et al (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426–2432PubMedCrossRef

Alvarez-Sabin J, Molina CA, Montaner J et al (2003) Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke 34:1235–1241PubMedCrossRef

McCormick MT, Muir KW, Gray CS et al (2008) Management of hyperglycemia in acute stroke: how, when, and for whom? Stroke 39:2177–2185PubMedCrossRef

Fuentes B, Castillo J, San JB et al (2009) The prognostic value of capillary glucose levels in acute stroke: the GLycemia in Acute Stroke (GLIAS) study. Stroke 40:562–568PubMedCrossRef

Gray CS, Hildreth AJ, Sandercock PA et al (2007) Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 6:397–406PubMedCrossRef

Diener HC, Putzki N et al (2008) Leitlinien der DGN 2008. In: Kommission „Leitlinien der Deutschen Gesellschaft für Neurologie“ (Hrsg.). Leitlinien für Diagnostik und Therapie in der Neurologie

Sacco RL, Adams R, Albers G et al (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 113:e409–e449PubMed

Yong M, Kaste M (2008) Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke 39:2749–2755PubMedCrossRef

10.

Task Force on Diabetes, Cardiovascular Diseases of the European Society of Cardiology (ESC), of the European Association for the Study of Diabetes (EASD) (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J Suppl 9:C3–C74CrossRef

11.

Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829–1839PubMedCrossRef

12.

Kurth T, Everett BM, Buring JE et al (2007) Lipid levels and the risk of ischemic stroke in women. Neurology 68:556–562PubMedCrossRef

13.

Sanossian N, Tarlov NE (2008) HDL-C and LDL-C: their role in stroke pathogenesis and implications for treatment. Curr Treat Options Cardiovasc Med 10:195–206PubMedCrossRef

14.

Bansal S, Buring JE, Rifai N et al (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309–316PubMedCrossRef

15.

Freiberg JJ, Tybjaerg-Hansen A, Jensen JS et al (2008) Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300:2142–2152PubMedCrossRef

16.

Bang OY, Saver JL, Liebeskind DS et al (2008) Association of serum lipid indices with large artery atherosclerotic stroke. Neurology 70:841–847PubMedCrossRef

17.

Kamstrup PR, Tybjærg-Hansen A, Steffensen R et al (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301:2331–2339PubMedCrossRef

18.

Amarenco P, Labreuche J (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8:453–463PubMedCrossRef

19.

Heart Protection Study Collaborative Group MRC/BHF (2002) Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet 360:7–22CrossRef

20.

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-dose atorvastatin after stroke or transient ischemic attack. New Engl J Med 355:549–559CrossRef

21.

Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022CrossRef

22.

Toole JF, Malinow MR, Chambless LE et al (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 291:565–575PubMedCrossRef

23.

Bonaa KH, Njolstad I, Ueland PM et al (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354:1578–1588PubMedCrossRef

24.

Lonn E, Yusuf S, Arnold MJ et al (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567–1577PubMedCrossRef

25.

Elkind MS (2009) Inflammatory markers and stroke. Curr Cardiol Rep 11:12–20PubMedCrossRef

26.

Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 14;340:115–126

27.

Di AE, Fiorelli M, Toni D et al (2005) Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 76:76–81CrossRef

28.

Ridker PM, Buring JE, Rifai N et al (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–619PubMedCrossRef

29.

Ridker PM, Cannon CP, Morrow D (2005) C-Reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20–28PubMedCrossRef

30.

Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRef

31.

Liman T, Endres M (2008) Elevated troponin and ECG alterations in acute ischemic stroke and subarachnoid hemorrhage. Nervenarzt 79:1386–1398PubMedCrossRef

32.

Jensen JK, Kristensen SR, Bak S et al (2007) Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol 99:108–112PubMedCrossRef

33.

James P, Ellis CJ, Whitlock RM et al (2000) Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ 320:1502–1504PubMedCrossRef

34.

Rubattu S, Sciarretta S, Valenti V et al (2008) Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 21:733–741PubMedCrossRef

35.

Kistorp C, Raymond I, Pedersen F et al (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609–1616PubMedCrossRef

36.

Adams HP, del Zoppo G, Alberts MJ et al (2007) Atherosclerotic peripheral vascular disease and quality of care outcomes in Research Interdisciplinary Working Groups. Stroke 38:1655–1711PubMedCrossRef

37.

38.

Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):401S–428SPubMedCrossRef

39.

Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295:1050–1057PubMedCrossRef

40.

Grau AJ, Weimar C, Buggle F et al (2001) Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32:559–566CrossRef

41.

Dimant J, Grob D (1977) Electrocardiographic changes and myocardial damage in patients with acute cerebrovascular accidents. Stroke 8:448–455PubMed

42.

Oppenheimer SA (1994) Neurogenic cardiac effects of cerebrovascular disease. Curr Opin Neurol 7:20–24PubMedCrossRef

43.

Oppenheimer SM, Hachinski VC (1992) The cardiac consequences of stroke. Neurol Clin 10:167–176PubMed

44.

Mikolich JR, Jacobs WC, Fletcher GF (1981) Cardiac arrhythmias in patients with acute cerebrovascular accidents. JAMA 246:1314–1317PubMedCrossRef

45.

Norris JF, Froggatt GM, Hachinski VC (1978) Cardiac arrhythmias in acute stroke. Stroke 9:392–396PubMed

46.

Jabaudon D, Sztajzel J, Sievert K et al (2004) Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 35:1647–1651PubMedCrossRef

47.

Marini C, De Santis F, Sacco S et al (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36:1115–1119PubMedCrossRef

48.

Tagawa M, Takeuchi S, Chinushi M et al (2007) Evaluating patients with acute ischemic stroke with special reference to newly developed atrial fibrillation in cerebral embolism. Pacing Clin Electrophysiol 30:1121–1128PubMedCrossRef

49.

Kirchhof P, Auricchio A, Bax J et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28:2803–2817PubMedCrossRef

50.

Fuster V, Ryden LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 27:1979–2030PubMedCrossRef

51.

Hohnloser SH, Pajitnev D, Pogue J et al (2007) Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 50:2156–2161PubMedCrossRef

52.

Glotzer TV (2008) The TRENDS Study: is there a critical value of daily atrial tachyarrhytmia burden from device diagnostics that raises stroke risk? ACC (abstract)

53.

Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867PubMed

54.

Mant J, Hobbs FD, Fletcher K et al (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA) a randomised controlled trial. Lancet 370:493–503PubMedCrossRef

55.

Hughes M, Lip GYH, Guideline Development Group (2008) National Clinical Guideline for management of atrial fibrillation in primary and secondary care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation, a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 99:295–304PubMed

56.

Connolly SJ, Ezwkowitz MD, Yusuf S, Eikelboom J, Oldgren J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 361(12):1139–1151PubMedCrossRef

57.

Fetsch T, Bauer P, Engberding D et al (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25:1385–1394PubMedCrossRef

58.

Page RL, Wilkinson WE, Clair WK et al (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89:224–227PubMed

59.

Botto G, Padeletti L, Santini M et al (2009) Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 20:241–248PubMedCrossRef

60.

Brignole M, Vardas P, Hoffman E et al (2009) Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 11:671–687PubMedCrossRef

61.

Barthelemy JC, Feasson-Gerard S, Garnier P et al (2003) Automatic cardiac event recorders reveal paroxysmal atrial fibrillation after unexplained strokes or transient ischemic attacks. Ann Noninvasive Electrocardiol 8:194–199PubMedCrossRef

62.

Hornig CR, Haberbosch W, Lammers C et al (1996) Specific cardiological evaluation after focal cerebral ischemia. Acta Neurol Scand 93:297–302PubMedCrossRef

63.

Liao J, Khalid Z, Scallan C et al (2007) Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 38:2935–2940PubMedCrossRef

64.

Rem JA, Hachinski VC, Boughner DR et al (1985) Value of cardiac monitoring and echocardiography in TIA and stroke patients. Stroke 16:950–956PubMed

65.

Schaer BA, Zellweger MJ, Cron TA et al (2004) Value of routine Holter monitoring for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemic events. Stroke 35:e68–e70PubMedCrossRef

66.

Schuchert A, Behrens G, Meinertz T (1999) Impact of long-term ECG recording on the detection of paroxysmal atrial fibrillation in patients after an acute ischemic stroke. Pacing Clin Electrophysiol 22:1082–1084PubMedCrossRef

67.

Shafqat S, Kelly PJ, Furie KL (2004) Holter monitoring in the diagnosis of stroke mechanism. Intern Med J 34:305–309PubMedCrossRef

68.

Miller VT, Pearce LA, Feinberg WM et al (1996) Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke prevention in Atrial Fibrillation Investigators. Neurology 46:238–240PubMed

69.

Hoppe UC, Casares JM, Eiskjaer H et al (2006) Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 114:18–25PubMedCrossRef

70.

Israel CW, Gronefeld G, Ehrlich JR et al (2004) Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 43:47–52PubMedCrossRef

71.

Capucci A, Santini M, Padeletti L et al (2005) Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 46:1913–1920PubMedCrossRef

72.

Glotzer TV, Hellkamp AS, Zimmerman J et al (2003) Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the mode selection trial (MOST). Circulation 107:1614–1619PubMedCrossRef

73.

Glotzer TV (2008) The TRENDS Study: is there a critical value of daily atrial tachyarrhythmia burden from device diagnostics that raises stroke risk? ACC (abstract)

74.

Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD (2009) The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2:474–480PubMedCrossRef

75.

Busse O, Darius H (2002) Indikationen zur Echokardiographie beim ischämischen zerebralen Insult. Nervenarzt 73:792–795PubMedCrossRef

76.

Flemming KD, Brown RD Jr, Petty GW et al (2004) Evaluation and management of transient ischemic attack and minor cerebral infarction. Mayo Clin Proc 79:1071–1086PubMedCrossRef

77.

Meissner I, Whisnant JP, Khandheria BK et al (1999) Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Mayo Clin Proc 74:862–869PubMedCrossRef

78.

Agmon Y, Khandheria BK, Gentile F et al (2002) Clinical and echocardiographic characteristics of patients with left atrial thrombus and sinus rhythm: experience in 20.643 consecutive transesophageal echocardiographic examinations. Circulation 105:27–31PubMedCrossRef

79.

Mas JL, Arquizan C, Lamy C et al (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 345:1740–1746PubMedCrossRef

80.

Giardini A, Donti A, Formigari R et al (2004) Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. Am J Cardiol 94:1012–1016PubMedCrossRef

81.

Handke M, Harloff A, Olschewski M et al (2007) Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 357:2262–2268PubMedCrossRef

82.

Overell JR, Bone I, Less KR (2000) Interatrial septal abnormalities and stroke. A meta-analysis of case-control studies. Neurology 55:1172–1179PubMed

83.

Serena J, Marti-Fàbregas J, Santamarina E et al (2008) Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke 39:3131–3139PubMedCrossRef

84.

Goel SS, Tuzcu EM, Shishehbor MH et al (2009) Morphology of the patent foramen ovale in asymptomatic versus symptomatic (stroke or transient ischemic attack) patients. Am J Cardiol 103:124–129PubMedCrossRef

85.

Weimar C, Holle DN, Benemann J, German Stroke Study Collaboration (2009) Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis 28:349–356PubMedCrossRef

86.

Homma S, Sacco RL, Di Tullio MR et al (2002) Effect of medical treatment in stroke patients with patent foramen ovale. Circulation 105:2625–2631PubMedCrossRef

87.

The European Stroke Organization (ESO) Executive Committee, the ESO Writing Committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457–507CrossRef

88.

Messe S, Silverman I, Kizer J et al (2004) Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 62:1042–1050PubMed

89.

Slottow TL, Steinberg DH, Waksman R (2007) Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices. Circulation 116:677–682PubMedCrossRef

90.

Hung J, Landzberg MJ, Jenkins KJ et al (2000) Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol 35:1311–1316PubMedCrossRef

91.

Khairy P, O’Donnell CP, Landzberg MJ (2003) Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 139:753–760PubMed

92.

Braun MU, Fassbender D, Schoen SP et al (2002) Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol 39:2019–2025PubMedCrossRef

93.

Windecker S, Wahl A, Chatterjee T et al (2000) Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 101:893–898PubMed

94.

Cifarelli A, Musto C, Parma A, Pandolfi C, Pucci E, Fiorilli R et al (2009) Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism. Int J Cardiol (Epub ahead of print)

95.

Berthet K, Lavergne T, Cohen A, Guize L, Bousser MG, Le Heuzey JY, Amarenco P (2003) Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 31(2):398–403

96.

Rigatelli G, Aggio S, Cardaioli P et al (2009) Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: an alternative concurrent mechanism for arterial embolism? JACC Cardiovasc Interv 2:655–662PubMedCrossRef

97.

Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–2537PubMedCrossRef

98.

Torti SR, Billinger M, Schwerzmann M et al (2004) Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J 25:2173–2174CrossRef

99.

Cartoni D, De Castro S, Valente G et al (2004) Identification of professional scuba divers with patent foramen ovale at risk for decompression illness. Am J Cardiol 94:270–273PubMedCrossRef

100.

Anzola G, Morandi E, Casilli F et al (2004) Does transcatheter closure of patent foramen ovale really “shut the door?”—a prospective study with transcranial doppler. Stroke 35:2140–2144PubMedCrossRef

101.

Cheitlin MD, Armstrong WF, Aurigemma GP et al (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 42:954–970PubMedCrossRef

102.

Witt BJ, Gami AS, Ballman KV et al (2007) The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 13:489–496PubMedCrossRef

103.

Pullicino PM, Halperin JL, Thompson JLP (2000) Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 54:288–294PubMed

104.

Massie BM, Collins JF, Ammon SE, WATCH Trial Investigators et al (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 119:1616–1624PubMedCrossRef

105.

Stroke Prevention in Atrial Fibrillation Study Group (1992) Predictors of thromboembolism in atrial fibrillation. Echocardiographic features of patients at risk. Ann Intern Med 116:6–1612

106.

Petty GW, Brown RD Jr, Whisnant JP et al (1999) Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 30:2513–2516PubMed

107.

Amarenco P, Röther J, Michel P et al (2006) Aortic arch atheroma and the risk of stroke. Curr Atheroscler Rep 8:343–346PubMedCrossRef

108.

Ringelstein EB, Arnold M, Dittrich R et al (2008) Dissektionen hirnversorgender supraaortaler Arterien. In: Kommission „Leitlinien der Deutschen Gesellschaft für Neurologie“ (Hrsg.). Leitlinien für Diagnostik und Therapie in der Neurologie 288–297

109.

Amarenco P, Cohen A, Tzourio C et al (1994) Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 331:1474–1479PubMedCrossRef

110.

Harloff A, Strecker C, Dudler P et al (2009) Retrograde embolism from the descending aorta: visualization by multidirectional 3D velocity mapping in cryptogenic stroke. Stroke 40:1505–1508PubMedCrossRef

111.

Krinsky G, Maya M, Rofsky N et al (1998) Gadolinium-enhanced 3D MRA of the aortic arch vessels in the detection of atherosclerotic cerebrovascular occlusive disease. J Comput Assist Tomogr 22:167–178PubMedCrossRef

112.

Ferrari E, Vidal R, Chevallier T et al (1999) Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: Benefit of oral anticoagulants. J Am Coll Cardiol 33:1317–1322PubMedCrossRef

113.

Mohr JP, Thompson JL, Lazar RM, Warfarin-Aspirin Recurrent Stroke Study Group (WARSS) et al (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444–1451PubMedCrossRef

114.

Tunick PA, Nayar AC, Goodkin GM et al (2002) Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 90:1320PubMedCrossRef

115.

Cannegieter S, Rosendaal F, Wintzen A et al (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11–17PubMedCrossRef

116.

Salem DN, Levine HJ, Pauker SG et al (1998) Antithrombotic therapy in valvular heart disease. Chest 114(Suppl):590–601CrossRef

117.

Bonow RO, Carabello BA, Chatterjee K et al (2008) Focused update incorporated into the ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) 008;118:e523–e661

118.

Gilon D, Bounanno FS, Joffe MM et al (1999) Lack of evidence of an association between mitral-valve prolapse and stroke in young patients. N Engl J Med 341:8–13PubMedCrossRef

119.

Baddour LM, Wilson WR, Bayer AS et al (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394–e434PubMedCrossRef

120.

Kapral MK, Silver FL, Preventive health care (1999) Update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. Canadian Task Force on Preventive Health Care. CMAJ 161:989–996PubMed

121.

Chiarella F, Santoro E, Domenicucci S et al (1998) Predischarge two-dimensional echocardiographic evaluation of left ventricular thrombosis after acute myocardial infarction in the GISSI-3 study. Am J Cardiol 81:822–827PubMedCrossRef

122.

Lerakis S, Nicholson WJ, Part I (2005) Use of echocardiography in the evaluation of patients with suspected cardioembolic stroke. Am J Med Sci 329:310–316PubMedCrossRef

123.

Peterson GE, Brickner ME, Reimold SC (2003) Transesophageal echocardiography: clinical indications and applications. Circulation 107:2398–2402PubMedCrossRef

124.

Zabalgoitia M, Halperin JL, Pearce LA et al (1998) Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 31:1622–1626PubMedCrossRef

125.

Bhatt DL, Steg PG, Ohman EM, REACH Registry Investigators et al (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295(2):180–189PubMedCrossRef

126.

Smith SC Jr, Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363–2372PubMedCrossRef

127.

Gohlke H, Albus C, Bönner G et al (2007) Leitlinie Risikoadjustierte Prävention von Herz- und Kreislauferkrankungen. Deutsche Gesellschaft für Kardiologie—Herz- und Kreislaufforschung e.V

128.

Graham I, Atar D, Borch-Johnsen K et al (2007) European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 14(Suppl 2):S1–S113PubMedCrossRef

129.

Röther J, Alberts MJ, Touzé E et al (2008) Steg on behalf of the REACH Registry Investigators Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry Cerebrovasc Dis 25:366–374

130.

Hankey GJ, Jamrozik K, Broadhurst RJ et al (2000) Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 31:2080–2086PubMed

131.

Nationale Versorgungsleitlinie (NVL) Chronische KHK (2006) Träger: Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. http://www.versorgungsleitlinien.de/themen/khk/pdf/nvl_khk_lang.pdf

132.

O’Rourke RA, Brundage BH, Froelicher VF et al (2000) American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102:126–140PubMed

133.

Baer FM (2007) Stress-ECG is the first step to assess myocardial ischemia: when are additional diagnostic tests needed? Dtsch med Wochenschr 132:2026–2030PubMedCrossRef

134.

Yilmaz A, Sechtem U (2008) Cardiac imaging in suspected coronary artery disease. Dtsch med Wochenschr 133:644–649PubMedCrossRef

135.

Tayal AH, Tian M, Kelly KM, Jones SC, Wright DG, Singh D, Jarouse J, Brillman J, Murali S, Gupta R (2008) Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 71(21):1696–1701

Titel: Cardiological evaluation after cerebral ischaemia
Consensus statement of the Working Group Heart and Brain of the German Cardiac Society—Cardiovascular Research (DGK) and the German Stroke Society (DSG)
verfasst von: Ulrich Laufs
Uta C. Hoppe
Stephan Rosenkranz
Paulus Kirchhof
Michael Böhm
Hans-Christoph Diener
Matthias Endres
Martin Grond
Werner Hacke
Thomas Meinertz
E. Bernd Ringelstein
Joachim Röther
Martin Dichgans
Publikationsdatum: 01.10.2010
Verlag: Springer-Verlag
Erschienen in: Clinical Research in Cardiology / Ausgabe 10/2010
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-010-0200-4

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2010

GRACE risk score as predictor of in-hospital mortality in patients with chest pain

Management of percutaneous self-expanding bioprosthesis migration

Time to rheology in acute myocardial infarction: inflammation and erythrocyte aggregation as a consequence and not necessarily as precursors of the disease

Relationship between pulse transit time and blood pressure is impaired in patients with chronic heart failure

Intracardial dislocation of a cranio-peritoneal shunt in a 6-year-old boy

Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points